Cosmos Health Expands Presence in the $7 Billion GCC Nutraceuticals Market, Signs Distribution Agreement with Scientific Pharmacy for Sky Premium Life in Oman, Including Initial Purchase Order of 42,000 Units
MWN-AI** Summary
Cosmos Health Inc. (NASDAQ:COSM) has made a significant move in the rapidly growing GCC nutraceuticals market by signing a distribution agreement with Scientific Pharmacy LLC for its Sky Premium Life food supplement products in Oman. With the GCC nutraceuticals market valued at approximately $6.91 billion in 2024 and projected to reach $15.5 billion by 2033, this strategic partnership positions Cosmos Health to leverage the increasing demand in the region driven by factors such as rising health awareness, higher disposable incomes, and government initiatives focused on lifestyle diseases.
Scientific Pharmacy, a subsidiary of Gulf Pharmaceutical Industries (Julphar), is recognized as a key healthcare and beauty player in Oman, with expertise in regulatory compliance, product registration, distribution, and retail services. Under the terms of the agreement, Scientific Pharmacy will manage all operations related to the distribution and marketing of Sky Premium Life products in Oman, supported by an initial purchase order of 42,000 units.
Greg Siokas, CEO of Cosmos Health, expressed enthusiasm about expanding into Oman, highlighting that the agreement not only reinforces their market presence but also reflects the quality and increasing global demand for their products. The firm anticipates substantial revenue growth as it taps into Scientific Pharmacy’s established retail and distribution channels.
Cosmos Health is a vertically integrated global healthcare group with a diverse portfolio of proprietary brands, including pharmaceuticals and nutraceuticals. The company is actively expanding its global footprint, which now includes operations in Europe, Asia, and North America, while also focusing on R&D initiatives targeting major health disorders. This entry into the Omani market marks a pivotal step for Cosmos Health in capturing a share of the burgeoning GCC nutraceuticals sector.
MWN-AI** Analysis
Cosmos Health Inc. (NASDAQ:COSM) has made a significant move into the rapidly growing GCC nutraceuticals market by signing a distribution agreement with Scientific Pharmacy LLC in Oman. This partnership and the subsequent initial purchase order of 42,000 units for the Sky Premium Life product line indicate a strategic expansion that aligns with market trends projecting the GCC nutraceuticals sector to grow from approximately $6.91 billion in 2024 to $15.5 billion by 2033.
The underlying growth drivers—such as heightened health awareness, increased disposable incomes, and government initiatives aimed at combating lifestyle diseases—create a favorable landscape for Cosmos. As Oman and surrounding GCC nations enhance their focus on health and wellness, this partnership places Cosmos at a strategic advantage, positioning its brand within a burgeoning market.
From an investment perspective, COSM’s foray into Oman represents both a diversification of its revenue streams and an opportunity to tap into an expanding market segment. The backing of Scientific Pharmacy, a well-established entity with a robust distribution and marketing infrastructure, enhances Cosmos's capability to penetrate the Omani market effectively. This agreement not only strengthens Cosmos’s market presence but also adds credibility to its Sky Premium Life brand amid rising consumer demand for high-quality nutraceuticals.
As investors consider Cosmos Health, they should take into account the potential for substantial revenue growth driven by this expansion. However, it is also essential to remain vigilant about possible future risks associated with foreign market entry, regulatory complexities, and competition within the nutraceuticals space. Investors might find COSM stock attractive for potential long-term gains, especially if it continues to execute its expansion strategy efficiently and capitalize on the growing health-consciousness in the GCC region.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CHICAGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Sky Pharm SA, signed a distribution agreement (the “Agreement”) with Scientific Pharmacy LLC (“Scientific Pharmacy”) for its Sky Premium Life food supplement products in Oman.
Scientific Pharmacy, the retail and wholesale arm of Planet Pharmacies in Oman, is a leading healthcare and beauty company offering integrated distribution and retail services. Known for its international brand partnerships and strong customer focus, it has become a trusted name in Oman and continues to expand across the Gulf Cooperation Council (GCC) region. Planet Pharmacies is owned by Gulf Pharmaceutical Industries (Julphar) , based in the United Arab Emirates, which is one of the largest pharmaceutical manufacturers in the Middle East and Africa, with annual revenue of approximately $350 million.
Under the Agreement, Scientific Pharmacy will manage all core activities, including regulatory compliance, product registration, distribution, marketing, logistics, and the retail sale of Sky Premium Life products across pharmacies and stores in Oman through its established retail and distribution network. The Agreement also includes an initial purchase order of 42,000 units.
According to IMARC Group , the GCC nutraceuticals market was valued at $6.91 billion in 2024 and is projected to reach $15.5 billion by 2033, with a CAGR of 8.7%. Growth is being driven by rising health awareness, higher disposable incomes, government initiatives addressing lifestyle diseases, rapid urbanization, and the expansion of retail and e-commerce channels.
Greg Siokas, CEO of Cosmos Health, stated: “We are excited to announce our expansion into Oman, further strengthening our presence in the rapidly growing nutraceuticals market across the GCC. This milestone showcases the exceptional quality of our products and the increasing global demand for our Sky Premium Life brand. We expect the agreement to generate significant revenue for Cosmos, supported by Scientific Pharmacy’s established retail and distribution network and the rising demand for premium food supplements in Oman.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com , www.skypremiumlife.com , www.cana.gr , www.zipdoctor.co , www.cloudscreen.gr , as well as LinkedIn and X .
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. Such forward-looking statements include, but are not limited to, the Company’s expectation that accumulation of ETH will enhance long-term shareholder value through increasing ETH-per-share, the Company’s plans to explore additional yield-generating strategies to optimize cash flow and utility from ETH holdings, that the Facility will provide access to growth capital to support a range of strategic initiatives, including accelerated product development, advanced R&D innovation, enhanced commercial initiatives, and the Company’s planned entry into U.S. manufacturing and the anticipated use of proceeds. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website ( www.sec.gov ). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
Disclaimer
This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a COSM financial position. COSM financial position and all other information regarding the featured Company should be verified directly with COSM. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in COSM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of COSM shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Compensation: Market Wire News and its affiliates has received six thousand dollars for Market Wire News advertising services from Relqo Media LLC for Brand Awareness Distribution, Corporate Communications, News, Press Release Enhancement and Social Media Solutions starting 2026-05-31 and ending 2026-06-05 provided by Market Wire News. To date, we have received a total of six thousand dollars. Please read our full disclaimer for compensation and more detailed information.
FAQ**
How does Cosmos Holdings Inc. COSM plan to leverage its distribution agreement with Scientific Pharmacy to penetrate the GCC nutraceuticals market, which is projected to grow to $15.5 billion by 2033?
What specific strategies will Cosmos Holdings Inc. COSM implement to capitalize on the rising health awareness and higher disposable incomes in Oman as outlined in the distribution agreement?
In terms of regulatory compliance and logistics, what unique advantages does Scientific Pharmacy offer that Cosmos Holdings Inc. COSM believes will ensure the successful rollout of Sky Premium Life products in Oman?
How does Cosmos Holdings Inc. COSM intend to utilize the initial purchase order of 42,000 units to drive brand recognition and market share within the competitive nutraceuticals landscape in Oman?
**MWN-AI FAQ is based on asking OpenAI questions about Cosmos Health Inc. (NASDAQ: COSM).
NASDAQ: COSM
COSM Trading
10.1% G/L:
$0.2758 Last:
1,618,807 Volume:
$0.2525 Open:
